TP53 and renal cell carcinoma: Therefore, TGase 2 is a possible therapeutic target for treating RCC, and this has been proved in a xenograft model.3 We found that DNA-damaging reagents such as doxorubicin enhance the p53 stability provided by the TGase 2 inhibitor GK921.